Complegent®

Complegent® Technology is a new technology developed by Kyowa Hakko Kogyo (now, Kyowa Hakko Kirin Co., Ltd.) Co., Ltd. that enhances one of the major mechanisms of action of an antibody, CDC. With an approach called isotype chimerism, in which portions of IgG3, an antibody’s isotype, are introduced into corresponding regions of IgG1, the standard isotype for therapeutic antibodies, Complegent® Technology significantly enhances CDC activity beyond that of either IgG1 or IgG3, while retaining the desirable features of IgG1, such as ADCC, PK profile and Protein A binding. In addition, it can be used together with Potelligent® Technology, creating an even superior therapeutic Mab (AccretaMab®) with enhanced ADCC and CDC activities.

click for larger

Click To Enlarge

click for larger

Click To Enlarge

The Benefits of Complegent® Technology

  • Enhances CDC activity more than 10-fold by Fc chimerism between IgG1 and IgG3
  • Retains desirable features of IgG1, including;

             – ADCC activity
             - PK profile
             - Protein A binding

  • Taps the naturally occurring sequence from IgG1 and IgG3
  • May be combined with Potelligent® Technology to create AccretaMab®, the ultimate enhanced antibody therapeutics (with both enhanced ADCC and CDC activities)